ORION Biotech Catalyst Calendar
Menu
Skip to company dates

Mannkind (MNKD) pipeline and stated timing

Pipeline at a glance

ProgramEventStageStated timingFiling
Afrezza (INHALE-1st)/data readoutStage not statedin late 20278-K ·

Source: ORION, orionbiotechai.com/company/MNKD, data as of Oct 17, 2026
https://www.orionbiotechai.com/company/MNKD

Latest retained statement: Afrezza (INHALE-1st) · Topline/data readout · in late 2027 · filed

SEC sources last checked .

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

Afrezza (INHALE-1st)

Matched

Topline/data readoutin late 2027

Stage: Not stated

Public float: $1,131,550,191 · as of · SEC filing

Data from this study is expected to be available in late 2027.

SEC timing context:

INHALE-1st: An additional eight sites have been activated to enroll participants into INHALE-1st, a study to evaluate the efficacy and safety of Afrezza plus basal insulin for youth aged 10-17 with newly-diagnosed type 1 diabetes.

8-K · Filed · Last checked

Source details

Accession 0001193125-26-243074

SEC accepted the filing

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .

Program / eventStated period and SEC wordingDisclosure in stated period
Afrezza (INHALE-1st)Clinical resultsin late 2027
“Data from this study is expected to be available in late 2027.”

Filed · 8-K

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Watch MNKD

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for MNKD. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology.

See MNKD in the calendar · Review labels and methodology

Topline results are the main summary results of a clinical trial, released before the full data.A Form 8-K is a report a company files with the SEC to announce a significant event between its regular reports.